IPP Bureau
We can create Seva Bhav by donating organs...: Dr. Mandaviya
By IPP Bureau - September 09, 2022
Despite having rich knowledge and defined responsibility, there has been less than expected response towards organ donation from our citizens
World BioProtection Forum India & Sharda University to host World BioProtection Summit – India 2022
By IPP Bureau - September 09, 2022
Two main objectives are: Accelerate novel technologies and products for global markets; and Connect academia and industry, creating synergy for faster advancement of the Bioprotection sector
Evonik appoints Dr. Gaetano Blanda as Head of Animal Nutrition Business Line
By IPP Bureau - September 08, 2022
Blanda will be responsible for overseeing Evonik’s amino acids and functional feed additives business and the expansion of its precision livestock farming approach
Honeywell to collaborate with leading health providers to advance digitalization of healthcare globally
By IPP Bureau - September 08, 2022
Aimed at improving patient outcomes and increasing connectivity for more efficient monitoring In hospitals and homes
Health Secretary addresses workshop on 'Roadmap to Strengthen Public Health Preparedness and Response Capabilities of Points of Entry (PoEs) in India'
By IPP Bureau - September 08, 2022
India is an example in front of the world to contribute towards strengthening Points of Entry during a public health emergency
President to launch Pradhan Mantri TB Mukt Bharat Abhiyaan on Sept 9
By IPP Bureau - September 08, 2022
The virtual event will be attended by representatives from state & district health administration, corporates, industries, civil society, and NGOs as the country reiterates its commitment towards TB elimination by 2025
Healthcare sector is expected to reach US $50 bn by 2025
By IPP Bureau - September 08, 2022
Healthcare has become more focused on innovation and technology over the past two years and 80% of healthcare systems are aiming to increase their investment in digital healthcare tools in the coming five years
Cipla receives US FDA approval for Revlimid (Lenalidomide) capsules
By IPP Bureau - September 08, 2022
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
SIRIO appoints Lonza’s Sara Lesina as General Manager in Europe
By IPP Bureau - September 08, 2022
Her appointment further strengthens the CDMO’s strategy to become the nutraceutical R&D hub for brands looking for agile partners with large scientific and development resources
World’s first intra nasal vaccine iNCOVACC from Bharat Biotech receives approval
By IPP Bureau - September 07, 2022
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
Football sized rare mesenteric tumour removed laparoscopically at the CK Birla Hospital
By IPP Bureau - September 07, 2022
In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery
Lupin and DKSH sign licensing and supply agreement to market five biosimilar candidates in the Philippines
By IPP Bureau - September 07, 2022
Lupin’s subsidiary in Philippines, Multicare Pharmaceuticals, will file for marketing approval and be responsible for distribution and commercialization of the biosimilars once approved.
Mandaviya virtually lays Foundation Stone of NCDC branches in 6 states
By IPP Bureau - September 07, 2022
NCDC branches in States/UTs will provide a boost to Public Health Infrastructurewith prompt surveillance, rapid detection and timely monitoring of diseases enabling Early Interventions
Lonza and Touchlight collaborate on end-to-end mRNA offering
By IPP Bureau - September 07, 2022
Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology
Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints
By IPP Bureau - September 06, 2022
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
